Background--Ion transport in the renal proximal tubule (RPT), which is increased in essential hypertension, is regulated by numerous hormones and humoral factors, including insulin and dopamine. Activation of dopamine receptor inhibits sodium reabsorption, whereas activation of insulin receptor increases sodium reabsorption in RPTs, and hyperinsulinemic animals and patients have defective renal dopaminergic system. We presume that there is an inhibition of D 4 receptor on insulin receptor expression and effect, and the regulation is lost in spontaneously hypertensive rats (SHRs).
tion. 1 Ion transport in the renal proximal tubule (RPT) is increased in essential hypertension, which is regulated by numerous hormones and humoral factors, including insulin and dopamine. 2, 3 Activation of dopamine receptor inhibits sodium reabsorption, whereas activation of insulin receptor increases sodium reabsorption in RPTs. 3, 4 Insulin has various effects. Besides its action on glucose metabolism, insulin affects blood pressure by regulation of vascular smooth muscle cellular proliferation, as well as renal salt and water excretion. [4] [5] [6] [7] Diabetes mellitus is associated with sodium and water retention. 8 There are evidences indicating that insulin, through stimulation of Na + /H + exchange and Na + -K + -ATPase activities directly, increases volume absorption in renal proximal tubules. 6 Dopamine is an endogenous catecholamine that modulates many cellular activities, including blood pressure and transmembrane ion transport. 3 Dopamine receptors are classified into the D 1 -like and D 2 -like subtypes based on their structure and pharmacology. D 1 -like receptors, comprised of D 1 and D 5 receptors, stimulate adenylyl cyclase activity, whereas D 2 -like receptors, comprised of D 2 , D 3 , and D 4 receptors, inhibit adenylyl cyclase activity, and regulate/ modulate activity of several ion channels. 3 Activation of D 1 -like or D 2 -like receptor induces natriuresis and diuresis. 9 Increasing pieces of evidence show interactions between insulin and dopamine receptors. [10] [11] [12] [13] Hyperinsulinemic animals and patients have a defective renal dopaminergic system 10 ; activation of dopamine receptor ameliorates insulin levels in obese humans and improves peripheral insulin sensitivity and renal function in streptozotocin (STZ)-induced type 2 diabetic rats. 11, 12 Because both D 4 receptor and insulin receptor exist in the RPTs, 13 we presume that activation of D 4 receptor inhibits insulin receptor expression and effect, which is aberrant in hypertensive states. In order to test the above hypotheses, we studied D 4 and insulin receptor interaction in immortalized RPT cells from Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs). These RPT cells behave similarly to freshly obtained RPT cells, at least with regard to dopamine receptors and responses to G-protein stimulation. 14, 15 Methods Cell Culture and Sample Preparation Immortalized RPT cells from microdissected S l segments of proximal tubules of 4-to 8-week-old WKY and SHRs were cultured at 37°C in a 95% air/5% CO 2 atmosphere in DMEM/ F-12 with transferrin (5 lg/mL), insulin (5 lg/mL), epidermal growth factor (10 ng/mL), dexamethasone (4 lg/mL), and FBS 5% on a 100-mm Petri dish. 16, 17 All animals in this study were handled in accord with the Guide for the Care and Use of Laboratory Animals of the Nation.
Cells were made quiescent by incubation for 2 hours in media without FBS before addition of reagents. Cells (80% confluence) were extracted in ice-cold lysis buffer, sonicated, kept on ice for 1 hour, and centrifuged at 16 000g for 30 minutes. All samples were stored at À70°C until use.
Immunoblotting
Insulin receptor antibody is polyconal rabbit antihuman antipeptide (Santa Cruz Biotechnology, Santa Cruz, CA). 18 Goat polyclonal p-insulin Rb antibody (Santa Cruz Biotechnology) was used as the phosphorylated insulin receptor antibody. RPT cells were treated with vehicle (dH 2 O), a D 4 receptor agonist (PD168077; Tocris Cookson Ltd, Bristol, UK), 19 or ABT724 (2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole trihydrochloride; Sigma-Aldrich, St. Louis, MO) or a D 4 receptor antagonist 20 (L-745870 [Tocris] or L750667 [Sigma-Aldrich]) at the indicated concentrations and times as described previously. 21 Transblots were probed with insulin receptor antibody (1:400). The amount of protein transferred onto membranes was determined by immunoblotting for a-actin.
Measurement of Intracellular Calcium Concentration
Twenty-four hours before the experiments, cells were harvested and seeded into 7.5-cm 2 Petri dishes (Falcon, Franklin Lakes, NJ). Cells were loaded with the calcium indicator, Fura-2AM (5 lmol/L), in HEPES buffered saline. Changes in intracellular calcium ([Ca 2+ ]) in individual cells were measured using an Aquacosmos system with band-pass filters for 340 and 380 nm. [Ca 2+ ]i was calculated from the Fura-2 fluorescence ratio (F340/F380) using linear regression between adjacent points on a calibration curve generated by measuring F340/F380 in at least 7 calibration solutions containing [Ca 2+ ] between 0 and 854 nmol/L. Ca 2+ concentration in individual groups were measured as previously described. 22 
Determination of the Second Messenger(s) Involved in Regulation of D 4 Receptor on Insulin Receptor Expression in WKY Cells
To determine the second messenger(s) involved in the regulation of D 4 on insulin receptor expression in WKY cells, several inhibitors or agonists were used: protein kinase C (PKC) inhibitor (PKC inhibitor 19-31, 10 À6 mol/L) 23 ; protein kinase A (PKA) inhibitor (PKA inhibitor 14-22, 10 À6 mol/L) 24 ; PKC activator (PMA, 10 À7 mol/L) 25 ; PKA activator (Sp-cAMPs, 10 À7 mol/L) 26 ; calcium-channel blocker (nicardipine, 10 À6 mol/L) 21 ; and calcium-channel agonist (BAY-K8644, 10 À6 mol/L). 27 Those reagents were added into the cell incubation medium 15 minutes before PD168077 treatment.
PKC inhibitor 19 to 31, PMA, Sp-cAMPs, nicardipine, and BAY-K8644 were purchased from Sigma-Aldrich. PKA inhibitor 14 to 22 was purchased from Calbiochem Company (Darmstadt, Germany).
Real-Time Polymerase Chain Reaction Detecting System of Insulin Receptors
A total of 2 to 3 lg of total RNA extracted from WKY and SHR cells were used to synthesize cDNA, which served as the template for amplification of receptor and b-actin (as a housekeeping gene). For b-actin, the forward primer was 5 0 -GTGGGTATGGGTCAGAAGGA-3 0 and the reverse primer was 5 0 -AGCGCGTAACCCTCATAGAT-3 0 (GeneBank Accession No.: NM031144). For insulin receptor, the forward primer was 5 0 -TTCAGGAAGACCTTCGAGGATTACCTGCAC-3 0 and the reverse primer was 5 0 -AGGCCAGAGATGACAAGTGACTCCTTGTT-3 0 (GeneBank Accession No.: X57764). Amplification was performed with the following conditions: denaturation at 95°C for 3 minutes, followed by 35 cycles at 95°C for 10 seconds and 60°C for 30 seconds. At the end of each run, a melting curve analysis was performed from 65°C to 95°C to monitor primer dimers or nonspecific product formation. Reactions were performed in triplicate. Insulin receptor mRNA expression was normalized for b-actin mRNA. 18 siRNA siRNA against D 4 receptor mRNA and its control scrambled RNA were synthesized and purified with reverse-phase high-performance liquid chromatography as 25-mer phosphoro-thioate-modified oligodeoxynucleotides (D 4 receptor siRNA sequence 5 0 -AAGGACCUCAAUGAAUAUGAAGAUAdTdT-3 0 ; scrambled RNA sequence: 5 0 -TGACGATAAGAACAATAACd TdT-3 0 ). Cells were grown in 6-well plates until 60% confluence, and 50 nmol/L of siRNA or control RNA were mixed with 6 lL of Oligofectamine in Opti-MEM medium (Invitrogen Life Technologies, Carlsbad, CA) and incubated for 24 hours, then switched to growth medium and incubated for another 24 hours. Cells were collected and processed for reversetranscription polymerase chain reaction for D 4 receptor to determine the efficiency of siRNA-induced D 4 receptor gene silencing.
Na + -K + -ATPase Activity Assay Na + -K + -ATPase activity was determined as the rate of inorganic phosphate released in the presence or absence of ouabain. 28, 29 Rat RPT cells were treated with vehicle (dH 2 O) and D 4 receptor agonist (PD168077) at the indicated concentrations and durations of incubation. To prepare membranes for Na + -K + -ATPase activity assay, RPT cells cultured in 21-cm 2 plastic culture dishes were collected and centrifuged at 3000g for 10 minutes. Cells were then placed on ice and lysed in 2 mL of lysis buffer (1 mmol/L of NaHCO 3 , 2 mmol/L of CaCl 2 and 5 mmol/L of MgCl 2 ). Cellular lysates were centrifuged at 3000g for 2 minutes to remove intact cells, debris, and nuclei. The resulting supernatant was suspended in an equal volume of 1 mol/L of sodium iodide, and the mixture was centrifuged at 48 000g for 25 minutes. The pellet (membrane fraction) was washed 2 times and suspended in 10 mmol/L of Tris containing 1 mmol/L of EDTA (pH 7.4). Protein concentrations were determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA) and adjusted to 1 mg/mL. Membranes were stored at À70°C until further use.
To measure Na + -K + -ATPase activity, 100-lL aliquots of membrane fraction were added to an 800-lL reaction mixture (75 mmol/L of NaCl, 5 mmol/L of KCl, 5 mmol/L of MgCl 2 , 6 mmol/L of sodium azide, 1 mmol/L of Na 4 EGTA, 37.5 mmol/L of imidazole, 75 mmol/L of Tris HCl, and 30 mmol/L of histidine; pH 7.4) with or without 1 mmol/L of ouabain (final volume=1 mL) and preincubated for 5 minutes in a water bath at 37°C. Reactions were initiated by adding Tris-ATP (4 mmol/L) and terminated after 15 minutes of incubation at 37°C by adding 50 lL of 50% trichloracetate. For determination of ouabain-insensitive ATPase activity, NaCl and KCl were omitted from the reaction mixtures containing ouabain. To quantify the amount of phosphate produced, 1 mL of coloring reagent (10% ammonium molybdate in 10 N of sulfuric acid+ferrous sulfate) was added to the reaction mixture. The mixture was then mixed thoroughly and centrifuged at 3000g for 10 minutes. Formation of phosphomolybdate was determined spectrophotometrically at 740 nm, against a standard curve prepared from K 2 HPO 4 . Na + -K + -ATPase activity was estimated as the difference between total and ouabain-insensitive ATPase activity and expressed as nmol phosphate released per mg protein per minute.
To eliminate the function of proteases and phosphatases, protease inhibitors (1 mmol/L of phenylmethylsulfonyl fluoride, 10 lg/mL of each leupeptin and aprotinin) and a phosphatase inhibitor (50 lmol/L of sodium orthovanadate) were added in all solutions used after drug/vehicle incubations.
Statistical Analysis
Data are expressed as meanAESEM. Comparison within groups was made by repeated-measures ANOVA (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by factorial ANOVA with Holm-Sidak test. A value of P<0.05 was considered significant.
Results

Activation of D 4 Receptor Decreases Insulin Receptor Expression in WKY RPT Cells
Stimulation of D 4 receptor with a D 4 agonist, PD168077, decreased insulin receptor expression in a concentrationdependent (10 À9 -10 À5 mol/L) and time-dependent (2-30 hours) manner in WKY RPT cells. The inhibitory effect was evident at 10 À8 mol/L, noted as early as 8 hours, and maintained for at least 30 hours ( Figure 1A and 1B) .
The specificity of PD168077 as a D 4 receptor agonist was also determined by studying the effect of the D 4 receptor antagonist, L745870. Consistent with the study shown in Figure 1A and 1B, PD168077 (10 À7 mol/L per 24 hours), decreased insulin receptor expression. The D 4 receptor antagonist, L745870 (10 À6 mol/L), by itself, had no effect on insulin receptor expression, but reversed the inhibitory effect of PD168077 on insulin receptor expression ( Figure 1C ).
To further confirm the regulation of D 4 receptor on insulin receptor expression, we used another D 4 It is reported that phosphorylation of insulin receptor will increase its function in RPT cells from both WKY and SHRs; it resulted that PD168077 (10 À7 mol/L per 24 hours) inhibited phosphorylation of insulin receptor in WKY cells, not in SHR cells (Figure 2A and 2B) . Morevoer, the D 4 receptor antagonist, L745870 (10 À6 mol/L), by itself, had no effect on insulin receptor phosphorylation, but reversed the inhibition of PD168077 on insulin receptor phosphorylation in WKY cells (Figure 2A ).
Extracellular and Intracellular Calcium Mediates the Inhibitory Effect of D 4 Receptor on Insulin Receptor Expression in RPT Cells
To investigate mechanisms of D 4 receptor induced downregulation of insulin receptor, WKY RPT cells were treated with different agonists or antagonists. Treatment with the calciumchannel blocker, nicardipine (10 À6 mol/L), or withdrawl of calcium from cell culture meidium blocked the inhibitory effect of D 4 receptor on insulin receptor expression ( Figure 3A and 3B), indicating that extracellular calcium influx was involved in the signal transduction pathway. To check whether intracellular calcium release from the endoplasmic reticulum was also involved in the mechanisms, we used inositol 1,4,5-trisphosphate (IP3) receptor blocker (2-aminoethyl diphenyl borate [2-ADB]; 10 À6 mol/L per 24 hours); the inhibitory effect of D 4 receptor on insulin receptor expression was abolished in the presence of IP3 blocker ( Figure 3C ), indicating that both extracellular calcium entry and calcium release from the Figure 3D -II); it resulted that BAY-K8644 or IP3 decreased insulin receptor expression in WKY RPT cells. The effect of PD168077 (10 À7 mol/L per 15 minutes) stimulation on intracellular calcium concentration in SHR and WKY RPT cells were further studied ( Figure 3E and 3F). We found that intracellular calcium concentration between SHR and WKY RPT cells have no significant difference in the basal level. PD168077 (10 À7 mol/L per 15 minutes) increased intracellular calcium in WKY RPT cells, but not in SHRs. This effect was blocked by the presence of nicardipine (10 À6 mol/L per 15 minutes) or 2-ADB (10 À6 mol/L per 15 minutes). We also evaluated the involvement of other key cell-signaling proteins with the use of a PKA inhibitor (PKA inhibitor 14-22, 10 À6 mol/L), PKC activator (PMA, 10 À7 mol/L), and PKA activator (Sp-cAMPs, 10 À7 mol/L). None of these reagents was able to block the inhibitory effect of insulin on D 5 receptor expression (data not shown).
D 4 Receptors Decrease Insulin Receptor Expression in WKY RPT Cells, not in SHR RPT Cells
To investigate whether there is a different regulation between WKY and SHRs, RPT cells from WKY and SHRs were treated with PD168077 (10 À7 mol/L) for 24 hours; consistent with the results in Figure 1A through 1C, activation of D 4 receptor decreased insulin receptor expression in WKY cells, but not in SHR cells ( Figure 4A ). We also investigated insulin receptor mRNA levels; consistent with protein results, activation of D 4 receptor with PD168077 (10 À7 mol/L per 24 hours) inhibited insulin receptor mRNA expression in WKY RPT cells, not in SHR cells ( Figure 4B ). In the presence of the calcium-channel blocker, nicardipine (10 À6 mol/L per 24 hours; Figure 4C -I), or IP3 receptor blocker (2-; 10 À6 mol/L per 24 hours; Figure 4C -II), dose regulation of D 4 receptor on insulin receptor mRNA expression was lost.
Pretreatment With D 4 Receptor Agonist Decreases the Stimulatory Effect of Insulin Receptor on Na + -K + -ATPase Activity in WKY RPT Cells, not in SHR RPT Cells
Effects of the D 4 agonist, PD168077 (10 À7 mol/L per 15 minutes), on Na + -K + -ATPase activity in WKY and SHR RPT cells were explored. Activity of Na + -K + -ATPase was higher in SHR than WKY RPT cells in the basal level. PD168077 inhibited Na + -K + -ATPase activity in WKY RPT cells, but not in SHR RPT cells ( Figure 5A ). The inhibitory effect was disappeared 2 hours after washing with PBS ( Figure 5B) . To investigate the physiological significance of D 4 receptor on insulin receptor expression, effects of insulin on Na + -K + - ATPase activity were determined in RPT cells from WKY and SHR cells. Insulin (10 À7 mol/L per 15 minutes) increased Na + -K + -ATPase activity, which was reduced by pretreatment with the D 4 receptor agonist, PD168077 (10 À7 mol/L per 24 hours), in WKY cells. However, in SHR cells, pretreatment with PD168077 had no effect on the insulin-mediated inhibitory effect on Na + -K + -ATPase activity in SHR cells ( Figure 5C ).
Discussion
Insulin receptor exists in RPTs; activation of insulin receptor induces antinatriuresis, which is supported by numerous previous studies. Early studies by Atchley et al. demonstrate that discontinuation of an insulin infusion to diabetic patients results in a brisk natriuresis. 30 Miller and Bogdonoff show that infusion of insulin into normal subjects results in a reduction in urinary sodium excretion. 31 Consistent with those studies, our present study found that insulin increases Na + -K + -ATPase activity in WKY cells and SHR cells. Dopamine receptor subtypes are expressed in specific segments of the mammalian kidney. The D 4 receptor has abundant protein expression in the proximal tubule. 3, 13 Previous studies show interactions between insulin and dopamine receptors. Hyperinsulinemic animals and patients with noninsulin-dependent diabetes have a defective renal dopaminergic system. 32 In obese Zucker rats, a model of type 2 diabetes, renal D 1 receptor are downregulated and dopamine fails to produce diuresis and natriuresis; treatment with insulin sensitizer rosiglitazone restores renal D 1 receptor effect. 33 Chronic exposure of cells to insulin causes both reduction in D 1 receptor abundance and its uncoupling from G proteins and diminishes the inhibitory effect of dopamine on Na + -K + -ATPase activity in hyperinsulinemic rats. 34 There are also evidences that activation of dopamine receptor influences insulin effect. Activation of D 2 receptor with bromocriptine simultaneously ameliorates insulin levels in obese humans. 11 Fenoldopam treatment improves peripheral insulin sensitivity and renal effect in STZ-induced type 2 diabetic rats. 12 Therefore, we hypothesize that D 4 receptor, along with step in the regulation of its function that is related to kinase activity. [35] [36] [37] We found that stimulation of D 4 receptor inhibits insulin receptor phosphorylation in WKY cells, but not in SHRs. It is in accord with the inhibition of D 4 receptor on effect of insulin receptor. The mechanism of the decrease in insulin receptors caused by D 4 receptors is not clear. Ca 2+ is suggested to be critical for expression of insulin receptor. DNA sequence analysis indicated that the promoter region of the gene contains several GGGCGG sequences that may be binding sites for the transcription factor, Sp1 (specificity protein 1). 38, 39 Sp1 could be upregulated by high Ca 2+ treatment. 40 Furthermore, Ca 2+ could stimulate phosphorylation of Sp1 and augment the activity of the gene promoter in an Sp1-binding-dependent manner. 41 Others also showed that the interactive role of cAMP regulatory element-binding protein and Sp1 is regulated by calcium. 42 As a D 2 -like receptor subtype, activation of D 4 receptor increases intracellular calcium concentration. 3 The present study showed that the inhibitory effect of D 4 receptor on insulin receptor expression is blocked by a calcium-channel blocker, withdrawal of calcium in the cell culture medium, or in the presence of IP3 receptor blocker, which blocks the calcium release from endoplasmic reticulum, indicating that calcium mobilization, including extracellular calcium influx and intracellular calcium release from the endoplasmic reticulum, is involved in the signaling pathway. Besides insulin receptor protein expression, our present study found that activation of D 4 receptor decreases insulin receptor mRNA expression in Then, cells were washed 3 times (15 min/times) with serum-free culture medium to remove all the added PD168077 and kept in serumfree culture medium for 2 hours before Na + -K + -ATPase activity was investigated (*P<0.05 vs control; # P<0.05 vs insulin; n=8). C, Cells were pretreated with PD168077 (10 À7 mol/L) or vehicle (dH 2 O) for 24 hours. After PD168077 pretreatment, cells were washed 3 times (15 min/times) with serum-free culture medium to remove all the added PD168077, kept in serum-free culture medium for 2 hours, and then treated with insulin (10 À7 mol/L) for 15 minutes. Results are expressed as percent change of control (*P<0.05 vs control; # P<0.05 vs insulin; n=8).
WKY cells. However, in the presence of a calcium-channel blocker or IP3 receptor blocker, the stimulatory effect of D 4 receptor on insulin receptor mRNA and protein expression is blocked. It indicates that the regulation may occur at the transcriptional/posttranscriptional level. The detailed mechanisms remain to be elucidated in the future. The pathogenesis of essential hypertension is complex; both genetic and environmental factors are involved. In hypertensive states, sodium reabsorption in RPTs is increased, 3 which is regulated by numerous hormones and humoral factors, including insulin and dopamine. In this study, we found that activation of D 4 receptor reduces insulin receptor expression and insulin-mediated sodium reabsorption by inhibition of Na + -K + -ATPase activity in the basolateral membranes of RPTs. It might indicate that D 4 receptor is a counterbalance against insulin receptor. However, inhibition of D 4 receptor on insulin receptor expression and effect is lost in SHRs, which might be involved in the pathogenesis of essential hypertension.
Conclusions
In summary, we have demonstrated that activation of D 4 receptor, by calcium mobilization from extracellular calcium influx and intracellular calcium release from the endoplasmic reticulum, decreases insulin receptor expression and insulinmediated stimulatory effect on Na + -K + -ATPase activity in WKY cells. However, in SHR cells, inhibition of D 4 receptor on insulin receptor expression and effect is lost, suggesting that aberrant inhibition of D 4 receptor on insulin receptor expression and effect might be involved in the pathogenesis of essential hypertension.
